Merative, a data, analytics and technology provider, is Morgan Health’s eighth portfolio company. The investment will help accelerate growth. The post Morgan Health Commits $25M to Merative to Enhance Employer Data Capabilities appeared first on MedCity News.
Keros Therapeutics will present Phase 2 data for the drug, elritercept, at the annual meeting of the American Society of Hematology. Meanwhile, the Takeda deal enables Keros to focus on two wholly owned assets, one of which could compete with a Merck drug approved earlier this year. The post Takeda Pays $200M for Keros Therapeutics…
Incorporating PbD into the software development process of EHR systems presents a strategy to protect information starting from the initial stages of development and, throughout the entire lifecycle of the software. The post Boosting HIPAA Compliance in EHR Systems with Privacy-by-Design appeared first on MedCity News.
When you combine clean data with longitudinal patient records and transparent access — that’s when you start seeing real transformation in care delivery. The post Set the Data Free: Break the Chains of Information Silos appeared first on MedCity News.
Philips is showcasing its partnerships and new products at RSNA 2024, including an expanded collaboration with AWS and a CT scanner that the company said uses up to 80% less radiation than traditional systems. The post 3 Innovations Philips Is Showcasing at RSNA 2024 appeared first on MedCity News.
Novartis is securing global rights to a PTC Therapeutics Huntington’s disease drug candidate that has encouraging Phase 2 data that will be discussed with the FDA to plan a pivotal study. Last year, Novartis discontinued its Huntington’s program after safety issues emerged in Phase 2 testing. The post Novartis Tries Again in Huntington’s, Putting Up…
In a recent report, Define Ventures revealed key insights from payers and providers on how they’re shaping their AI strategies. The post 4 Key Insights into Payer and Provider Leaders’ Vision for AI appeared first on MedCity News.
The FDA cited deficiencies in its govorestat’s application in galactosemia, a rare metabolic disease, Applied Therapeutics said. The biotech is still on track to submit a separate application for the drug in sorbitol dehydrogenase (SORD) deficiency, another rare disease that has no FDA-approved therapies. The post Applied Therapeutics Drug Is Denied FDA Approval in Rare…
Besides the impact to physician satisfaction, the cost of this administrative burden is staggering: Organizations spend $82.7 billion annually on documentation, coding, and other administrative tasks, straining both budgets and staff. The post Tackling Burnout: How AI Lifts the Coding Burden on Physicians appeared first on MedCity News.
It’s about interpreting the full range of factors, from biology to life circumstances, that can push someone to the edge. The post A New Perspective on Suicide: It’s More Than Just Depression appeared first on MedCity News.